Crispr Therapeutics Viking Therapeutics: 2026 Stock Showdown
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
This brief describes typical assets that make up an equal weighted index and how diverse holdings contribute to balanced exposure and performance.
17,287 articlesAs biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
A top institutional trader doubled down on PTCT, adding thousands of shares in a high-conviction move. This analysis ...
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Trump signals possible U.S. ground action against Mexican cartels, sending ripples through defense stocks and supply ...
Energy Select Sector SPDR Fund (XLE) has staged a rebound as crude hits higher levels. Two key signals could set the ...
Celebrity moments on luxury yachts captivate fans and investors alike. This article dissects the financial impact of ...
Roku and Sirius XM sit at opposite ends of the media stock spectrum: one is a fast-growing platform, the other a stea...
Looking to find a better space stock: spacemobile? This guide breaks down AST SpaceMobile and Rocket Lab, weighing te...
In a landscape defined by budget cycles and rapid tech shifts, L3Harris Technologies stands out with a 7.1 rating in ...
As Xeris prepares to unpack its Q1 2026 results, investors want clarity on revenue, cash runway, and pipeline milesto...
What could Palantir's stock do by the end of 2027? This article builds three forward-looking scenarios, weighs risks,...
After a string of near-misses, Netflix finally makes acquisition that seems to align with its long-term plan. This pi...